vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and VSE CORP (VSEC). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $301.2M, roughly 1.6× VSE CORP). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 4.5%, a 2.3% gap on every dollar of revenue. On growth, VSE CORP posted the faster year-over-year revenue change (0.7% vs -1.7%). Over the past eight quarters, VSE CORP's revenue compounded faster (11.7% CAGR vs -0.1%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

VSE Corporation is a leading provider of aftermarket distribution and repair services. Operating through its two key segments, VSE significantly enhances the productivity and longevity of its customers' high-value, business-critical assets. The aviation segment is a leading provider of aftermarket parts distribution and maintenance, repair, and overhaul (MRO) services for components and engine accessories to commercial, business, and general aviation operators. The fleet segment specializes i...

MD vs VSEC — Head-to-Head

Bigger by revenue
MD
MD
1.6× larger
MD
$493.8M
$301.2M
VSEC
Growing faster (revenue YoY)
VSEC
VSEC
+2.4% gap
VSEC
0.7%
-1.7%
MD
Higher net margin
MD
MD
2.3% more per $
MD
6.8%
4.5%
VSEC
Faster 2-yr revenue CAGR
VSEC
VSEC
Annualised
VSEC
11.7%
-0.1%
MD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MD
MD
VSEC
VSEC
Revenue
$493.8M
$301.2M
Net Profit
$33.7M
$13.6M
Gross Margin
Operating Margin
9.9%
10.8%
Net Margin
6.8%
4.5%
Revenue YoY
-1.7%
0.7%
Net Profit YoY
10.5%
3.9%
EPS (diluted)
$0.40
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
VSEC
VSEC
Q4 25
$493.8M
$301.2M
Q3 25
$492.9M
$282.9M
Q2 25
$468.8M
$272.1M
Q1 25
$458.4M
$256.0M
Q4 24
$502.4M
$299.0M
Q3 24
$511.2M
$273.6M
Q2 24
$504.3M
$266.0M
Q1 24
$495.1M
$241.5M
Net Profit
MD
MD
VSEC
VSEC
Q4 25
$33.7M
$13.6M
Q3 25
$71.7M
$3.9M
Q2 25
$39.3M
$3.2M
Q1 25
$20.7M
$-9.0M
Q4 24
$30.5M
$13.1M
Q3 24
$19.4M
$11.7M
Q2 24
$-153.0M
$-2.8M
Q1 24
$4.0M
$-6.6M
Operating Margin
MD
MD
VSEC
VSEC
Q4 25
9.9%
10.8%
Q3 25
13.8%
3.6%
Q2 25
12.8%
8.3%
Q1 25
7.0%
9.6%
Q4 24
7.8%
9.2%
Q3 24
6.6%
8.7%
Q2 24
-31.3%
2.3%
Q1 24
3.2%
10.0%
Net Margin
MD
MD
VSEC
VSEC
Q4 25
6.8%
4.5%
Q3 25
14.5%
1.4%
Q2 25
8.4%
1.2%
Q1 25
4.5%
-3.5%
Q4 24
6.1%
4.4%
Q3 24
3.8%
4.3%
Q2 24
-30.3%
-1.0%
Q1 24
0.8%
-2.7%
EPS (diluted)
MD
MD
VSEC
VSEC
Q4 25
$0.40
$0.64
Q3 25
$0.84
$0.19
Q2 25
$0.46
$0.16
Q1 25
$0.24
$-0.44
Q4 24
$0.37
$0.79
Q3 24
$0.23
$0.63
Q2 24
$-1.84
$-0.16
Q1 24
$0.05
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
VSEC
VSEC
Cash + ST InvestmentsLiquidity on hand
$375.2M
$69.4M
Total DebtLower is stronger
$570.5M
$292.8M
Stockholders' EquityBook value
$865.9M
$1.4B
Total Assets
$2.2B
$2.0B
Debt / EquityLower = less leverage
0.66×
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
VSEC
VSEC
Q4 25
$375.2M
$69.4M
Q3 25
$340.1M
$8.8M
Q2 25
$224.7M
$16.9M
Q1 25
$99.0M
$5.7M
Q4 24
$229.9M
$29.0M
Q3 24
$103.8M
$7.9M
Q2 24
$19.4M
$19.0M
Q1 24
$8.0M
$10.6M
Total Debt
MD
MD
VSEC
VSEC
Q4 25
$570.5M
$292.8M
Q3 25
$577.2M
$356.1M
Q2 25
$583.9M
$379.2M
Q1 25
$590.5M
$465.0M
Q4 24
$597.1M
$430.2M
Q3 24
$450.3M
Q2 24
$463.5M
Q1 24
$481.6M
Stockholders' Equity
MD
MD
VSEC
VSEC
Q4 25
$865.9M
$1.4B
Q3 25
$890.7M
$983.3M
Q2 25
$833.8M
$979.5M
Q1 25
$789.2M
$975.7M
Q4 24
$764.9M
$988.2M
Q3 24
$732.5M
$787.8M
Q2 24
$706.5M
$781.3M
Q1 24
$856.2M
$612.7M
Total Assets
MD
MD
VSEC
VSEC
Q4 25
$2.2B
$2.0B
Q3 25
$2.2B
$1.6B
Q2 25
$2.1B
$1.6B
Q1 25
$2.0B
$1.7B
Q4 24
$2.2B
$1.7B
Q3 24
$2.1B
$1.5B
Q2 24
$2.0B
$1.5B
Q1 24
$2.2B
$1.3B
Debt / Equity
MD
MD
VSEC
VSEC
Q4 25
0.66×
0.20×
Q3 25
0.65×
0.36×
Q2 25
0.70×
0.39×
Q1 25
0.75×
0.48×
Q4 24
0.78×
0.44×
Q3 24
0.57×
Q2 24
0.59×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
VSEC
VSEC
Operating Cash FlowLast quarter
$114.1M
$37.6M
Free Cash FlowOCF − Capex
$30.9M
FCF MarginFCF / Revenue
10.3%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
3.39×
2.77×
TTM Free Cash FlowTrailing 4 quarters
$5.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
VSEC
VSEC
Q4 25
$114.1M
$37.6M
Q3 25
$137.3M
$24.1M
Q2 25
$137.2M
$11.9M
Q1 25
$-117.5M
$-46.6M
Q4 24
$133.0M
$55.4M
Q3 24
$91.8M
$10.2M
Q2 24
$107.0M
$-17.5M
Q1 24
$-125.2M
$-79.1M
Free Cash Flow
MD
MD
VSEC
VSEC
Q4 25
$30.9M
Q3 25
$18.0M
Q2 25
$6.3M
Q1 25
$-49.5M
Q4 24
$52.1M
Q3 24
$4.4M
Q2 24
$-21.5M
Q1 24
$-86.8M
FCF Margin
MD
MD
VSEC
VSEC
Q4 25
10.3%
Q3 25
6.4%
Q2 25
2.3%
Q1 25
-19.3%
Q4 24
17.4%
Q3 24
1.6%
Q2 24
-8.1%
Q1 24
-35.9%
Capex Intensity
MD
MD
VSEC
VSEC
Q4 25
2.2%
Q3 25
2.1%
Q2 25
2.1%
Q1 25
1.1%
Q4 24
1.1%
Q3 24
2.1%
Q2 24
1.5%
Q1 24
3.2%
Cash Conversion
MD
MD
VSEC
VSEC
Q4 25
3.39×
2.77×
Q3 25
1.91×
6.16×
Q2 25
3.49×
3.72×
Q1 25
-5.66×
Q4 24
4.36×
4.24×
Q3 24
4.72×
0.87×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

VSEC
VSEC

Segment breakdown not available.

Related Comparisons